Share
   
Title
Code
Session Type
Venue
Date Time
Co-Chairs:

All treatment guidelines agree that every individual should receive treatment for HIV and associated comorbidities, in particular tuberculosis and hepatitis C. If treatments were priced at $90, or less, a year, a major treatment access barrier – cost - would be removed. This multi-perspective session discusses and analyzes the barriers to global affordable drug pricing. It examines how therapeutics could become affordable, as currently, prices are variable worldwide and often high. The increasingly important role of advocacy, together with commitments by pharmaceuticals, originator and generic, for affordable therapeutics are debated and discussed in this session, which is directed towards policymakers, programme managers, and community advocates. It offers perspectives from the industry, NGOs, academia, and community participants and allows delegates to gain an understanding of issues related to the affordable pricing of essential medicines for HIV and comorbidities and the ability to identify the various forces shaping costs.

14:30
WESY0402
$90-$90-$90: how we can achieve these access prices
Andrew Hill, University of Liverpool, United Kingdom
Slides
14:38
WESY0403
Navigating and negotiating lower prices
Margaret Hellard, Burnet Institute, Australia
Slides
14:46
WESY0404
How pricing can improve access to treatment
Sergey Golovin, International Treatment Preparedness Coalition (ITPC), Russian Federation
Slides
14:54
WESY0405
How advocacy can influence pricing policy
Jessica Burry, Access Campaign, Canada
Slides
15:02
WESY0406
How pharma are responding to the challenge
Manuel Goncalves, ViiV Healthcare, United Kingdom
15:10
WESY0407
How generic companies can upscale treatment affordably instead of cheaply
Helmy Sherine, Pharco Pharmaceuticals, Egypt
Slides
15:18
WESY0408
Moderated discussion
15:48
WESY0409
Closing remarks